ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit

NEW YORK, Oct. 15, 2024 /PRNewswire/ -- 

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the "Class Period"), of the important November 12, 2024 lead plaintiff deadline.

So what: If you purchased Allarity securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Allarity class action, go to https://rosenlegal.com/submit-form/?case_id=27420 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 12, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) defendants had overstated the Dovitinib, Allarity's drug candidate which treats renal cell carcinoma, new drug application's ("NDA") continued regulatory prospects; (2) Allarity and three of its former officers had engaged in illegal, illicit, and/or otherwise improper conduct in connection with the Dovitinib NDA and/or the Dovitinib-DRP premarket approval application ("PMA"); (3) the foregoing misconduct subjected Allarity to an increased risk of regulatory and/or governmental scrutiny and enforcement action, as well as significant legal, monetary, and reputational harm; (4) following Allarity's announcement that it was, in fact, being investigated for wrongdoing in connection with the Dovitinib NDA and/or the Dovitinib-DRP PMA, Allarity downplayed the substantial likelihood that an enforcement action would result from such investigation; and (5) as a result, Allarity's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Allarity class action, go to https://rosenlegal.com/submit-form/?case_id=27420 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.

      Phillip Kim, Esq.

      The Rosen Law Firm, P.A.

      275 Madison Avenue, 40th Floor

      New York, NY 10016

      Tel: (212) 686-1060

      Toll Free: (866) 767-3653

      Fax: (212) 202-3827

      case@rosenlegal.com

      www.rosenlegal.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/allr-investors-have-opportunity-to-lead-allarity-therapeutics-inc-securities-fraud-lawsuit-302277109.html

SOURCE THE ROSEN LAW FIRM, P. A.